Strategies For Selecting New Indications For A Platform Trial
By Esha Senchaudhuri
The increasing use of platform trials for the testing of a wide range of therapies raises new questions for trial design optimization and simulation. A challenge, however, is ensuring that strategies for selecting new indications for a platform are built into the risk-mitigation strategies that often go into optimizing trial design. In other words, a part of de-risking a platform trial requires a design that is robust and flexible for unknown indications that could be added in the future. In a recent Cytel webinar, Dr. Kyle Wathen, VP of Scientific Strategy and Innovation, examines this and related issues.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.